At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study

- This is the first readout of two-year Phase 2 data of an anti-IL-23p19 antibody for the treatment of moderately to severely active ulcerative colitis - - 92% of participants stayed on mirikizumab throughout one-year maintenance period; 83% continued mirikizumab through two years - INDIANAPOLIS ,